Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to predict potential drug–drug interactions (DDIs). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Diansong, Podoll, Terry, Xu, Yan, Moorthy, Ganesh, Vishwanathan, Karthick, Ware, Joseph, Slatter, J. Greg, Al‐Huniti, Nidal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656940/
https://www.ncbi.nlm.nih.gov/pubmed/31044521
http://dx.doi.org/10.1002/psp4.12408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656940/
https://www.ncbi.nlm.nih.gov/pubmed/31044521
http://dx.doi.org/10.1002/psp4.12408

Ejemplares similares